Skip to main content

Master of Public Health

Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAF(V600E) In Vivo.

AUTHORS

Schulte ML , Hight MR , Ayers GD , Liu Q , Shyr Y , Washington MK , Manning HC , . Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging. 2016 10 21; ().
  • NIHMSID: 101125610

ABSTRACT

This study aimed to study whether cancer cells possess distinguishing metabolic features compared with surrounding normal cells, such as increased glutamine uptake. Given this, quantitative measures of glutamine uptake may reflect critical processes in oncology. Approximately, 10 % of patients with colorectal cancer (CRC) express BRAF (V600E) , which may be actionable with selective BRAF inhibitors or in combination with inhibitors of complementary signaling axes. Non-invasive and quantitative predictive measures of response to these targeted therapies remain poorly developed in this setting. The primary objective of this study was to explore 4-[(18)F]fluoroglutamine (4-[(18)F]F-GLN) positron emission tomography (PET) to predict response to BRAF(V600E)-targeted therapy in preclinical models of colon cancer.

This study aimed to study whether cancer cells possess distinguishing metabolic features compared with surrounding normal cells, such as increased glutamine uptake. Given this, quantitative measures of glutamine uptake may reflect critical processes in oncology. Approximately, 10 % of patients with colorectal cancer (CRC) express BRAF (V600E) , which may be actionable with selective BRAF inhibitors or in combination with inhibitors of complementary signaling axes. Non-invasive and quantitative predictive measures of response to these targeted therapies remain poorly developed in this setting. The primary objective of this study was to explore 4-[(18)F]fluoroglutamine (4-[(18)F]F-GLN) positron emission tomography (PET) to predict response to BRAF(V600E)-targeted therapy in preclinical models of colon cancer.

Tags: